^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CXCL9 (Chemokine (C-X-C motif) ligand 9)

    i
    Other names: CXCL9, CMK, crg-10, Humig, MIG, SCYB9, Chemokine (C-X-C motif) ligand 9
    5d
    In Silico Transcriptomic Analysis for Identification of Potential Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Cervical Cancer using a Hybrid Genetic Algorithm-Support Vector Machine Approach. (PubMed, Arch Iran Med)
    The identified gene signatures may serve as candidates for hypothesis generation and provide a computational framework to prioritize biomarkers and therapeutic targets in cervical cancer. However, these findings are based on in silico analyses and require experimental and clinical validation before translation into practice.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • DNMT1 (DNA methyltransferase 1) • AURKB (Aurora Kinase B) • PCNA (Proliferating cell nuclear antigen) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • TP63 (Tumor protein 63) • CDK1 (Cyclin-dependent kinase 1) • MMP1 (Matrix metallopeptidase 1) • MYBL2 (MYB Proto-Oncogene Like 2) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2) • CCNB1 (Cyclin B1) • CTGF (Connective tissue growth factor) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • E2F1 (E2F transcription factor 1) • KPNA2 (Karyopherin Subunit Alpha 2) • SLC5A1 (Solute Carrier Family 5 Member 1)
    5d
    The ATF5-GPER1 axis drives female protection in hepatocellular carcinoma through dual tumor-suppressive and immune-modulatory mechanisms. (PubMed, Biosci Trends)
    Tissue microarray validation (n = 167) confirmed high ATF5 expression predicts improved recurrence-free survival specifically in female patients (HR = 0.34, p = 0.040) but not males (p = 0.080). The ATF5-GPER1 axis represents a female-protective circuit operating through tumor-intrinsic suppression and immune remodeling, offering mechanistic insight into HCC sexual dimorphism and identifying ATF5 as a sex-specific prognostic biomarker with potential therapeutic implications.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • GPER1 (G Protein-Coupled Estrogen Receptor 1)
    9d
    Integrated single-cell and spatial analysis reveals context-dependent myeloid-T cell interactions in response to immune checkpoint blockade in head and neck cancer. (PubMed, Clin Cancer Res)
    We have provided a valuable resource for analyzing spatial and cell-cell ligand-receptor interactions, including the cellular and spatial contexts of ICB response markers. Our data suggest that future mechanistic studies should consider this context specificity when evaluating ICB response biomarkers and targets.
    Journal • Checkpoint inhibition
    |
    CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • CXCL16 (C-X-C Motif Chemokine Ligand 16)
    10d
    AARS1-mediated lactylation of STAT1 drives immune evasion. (PubMed, Cell Rep)
    Furthermore, we developed a cell-penetrating peptide, K193-pe, that can competitively inhibit STAT1 K193 lactylation and re-sensitize tumor cells to IFN-γ signaling, thus enhancing CD8+ T cell recruitment and improving the efficacy of immune checkpoint blockade therapy. Collectively, this study elucidates the functional significance of STAT1 K193 lactylation in tumor immunity and suggests that targeted inhibition of this modification, when paired with immunotherapy, may offer a viable treatment strategy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • STAT1 (Signal Transducer And Activator Of Transcription 1)
    12d
    Bioinformatic analysis of the potential common pathogenic mechanisms for gastric precancerous lesions and Helicobacter pylori. (PubMed, Front Gastroenterol (Lausanne))
    These findings may provide insights for identifying disease biomarkers, inhibiting the "inflammation-cancer" transformation, and preventing GC. Furthermore, the targets and molecular mechanisms identified in this study require further experimental validation to confirm their therapeutic potential.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • IL6 (Interleukin 6) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • CCL3 (C-C Motif Chemokine Ligand 3)
    13d
    Molecular remodeling of cancer-associated fibroblasts in breast cancer patients receiving anti-PD-1 immunotherapy. (PubMed, Front Oncol)
    Collectively, these findings highlight the critical role of CAF heterogeneity and spatial organization in modulating the response to anti-PD-1 therapy. Targeting subtype-specific stromal modules may represent a promising therapeutic strategy to enhance the efficacy of immunotherapy in breast cancer.
    Journal
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • THBS2 (Thrombospondin 2)
    16d
    TDO2-Associated Tryptophan Metabolism Correlates with Impaired Tertiary Lymphoid Structure Maturation and Reduced B Cell Class Switching in Breast Cancer. (PubMed, Oncol Res)
    In conclusion, our findings suggest that TDO2-associated tryptophan metabolism is linked to impaired TLS maturation and suppressed B cell class switching in breast cancer. Targeting the TDO2-kynurenine axis may represent a promising strategy to restore TLS formation and enhance immunotherapy responsiveness in breast cancer.
    Journal • BRCA Biomarker • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • BRCA (Breast cancer early onset) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • TDO2 (Tryptophan 2,3-Dioxygenase)
    18d
    Targeting cellular source-specific CXCL9 signaling for immunotherapy in oral squamous cell carcinoma. (PubMed, Front Immunol)
    Instead, overcoming ICB resistance in OSCC requires a precision strategy focused on targeting cell-specific CXCL9 signaling. Ultimately, dissecting and therapeutically navigating the source-specific CXCL9 network is essential to transform the OSCC TME and improve clinical outcomes.
    Review • Journal
    |
    CXCL9 (Chemokine (C-X-C motif) ligand 9)
    19d
    Macrophage-rich niches regulate T cell dynamics at the liver invasive margin during gallbladder cancer progression. (PubMed, J Clin Invest)
    In addition, our cohort study showed that high CXCL9 and low LGALS4 in the liver invasion margin demonstrated a favorable prognosis and better responses to anti-PD-1 immunotherapy for patients with gallbladder cancer. Altogether, these findings demonstrate novel cellular and molecular mechanisms underlying liver invasion and offer clinical value for immunotherapies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • LGALS4 (Galectin 4) • C1QB (Complement C1q B Chain)
    21d
    Immune Network Construction and Prognostic Evaluation of Checkpoint Genes in Endometrial Cancer Using STRING, MCODE, and GEPIA2. (PubMed, Cancer Diagn Progn)
    This in silico immune network highlights checkpoint centered hubs and coordinated immune programs with prognostic relevance in endometrial cancer, providing a rationale for biomarker guided immunotherapy development and patient stratification. Validation in independent cohorts and correlation with clinicopathologic and treatment response data are needed to support clinical translation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PD-L2 (Programmed Cell Death 1 Ligand 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • ICOS (Inducible T Cell Costimulator) • GZMB (Granzyme B) • TBX21 (T-Box Transcription Factor 21) • FOXP3 (Forkhead Box P3) • CD40 (CD40 Molecule) • PRF1 (Perforin 1) • LGALS9 (Galectin 9)
    22d
    VISTA drives pancreatic tumor progression through modulation of the tumor-associated macrophage polarity. (PubMed, Nat Commun)
    These findings are corroborated by human PDAC data, which reflect similar immune reprogramming trends. By defining the role of VISTA in controlling Cxcl9:Spp1 ratio and modulating CD8⁺ T cell dynamics, this study positions VISTA inhibition as a promising strategy to reshape the TME and potentiate anti-tumor immunity in PDAC.
    Journal
    |
    CD8 (cluster of differentiation 8) • SPP1 (Secreted Phosphoprotein 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
    26d
    CXCL9 as a key feature for deep learning-based immune subtyping and prediction of immune checkpoint blockade response in triple-negative breast cancer. (PubMed, Int Immunopharmacol)
    Our study developed a novel immune classification system for TNBC, identifying CXCL9 as a key biomarker positively correlated with ICB response and regulated by IDO1. These findings provide a basis for precision immunotherapy in TNBC and support the exploration of IDO1 inhibitors in combination with ICB.
    Journal • Checkpoint inhibition • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CXCL9 (Chemokine (C-X-C motif) ligand 9)
    |
    PD-L1 expression • PD-L1 overexpression